Novo Nordisk to reduce prices of two insulin products in the US by more than 70%
Danish drugmaker Novo Nordisk said on Thursday it will cut the US list prices of two insulin products by more than 70% from January 2026. List prices for its insulin drug Fiasp will be cut by 75%, while list prices for its insulin Tresiba will be cut by 72.2%.
POPULAR POSTS
Earthquakes and emissions undermine the idea of carbon storage in Texas
December 17, 2024
Rescuers search for cyclone survivors in devastated Mayotte
December 17, 2024
“Gilmore Girls” airs for a second season on Hulu
December 17, 2024
LIVE STREAM
